Bextra trial delay doesn't sit well with plaintiff Man's family says it is still waiting for Pfizer to make a settlement offer The woman whose case against Pfizer Inc.over the death of her husband was expected to set the tone for Bextra lawsuits everywhere has not yet received a ...
Pharmaceutical giant McKesson pays $13.3M in settlement McKesson Corp.of San Francisco, one of the nations largest pharmaceutical distributors, agreed to pay $13.3 million to settle federal charges that it failed to report suspicious orders for painkillers and weight-loss drugs.
McKesson...
Pharmaceutical giant pays $13.3M in federal settlement McKesson Corp.of San Francisco, one of the nations largest pharmaceutical distributors, agreed to pay $13.3 million to settle federal charges that it failed to report suspicious orders for painkillers and weight-loss drugs.
McKesson...
Mylan In Settlement Talks With Abbott On Generic Depakote NEW YORK -(Dow Jones)- Mylan Inc.(MYL) is in talks to settle the ongoing litigation in its attempt to sell a generic of the extended-release version of Abbott Laboratories' (ABT) Depakote seizure medication.
'We are in negotiation ...
Caliper Life Sciences Reports First Quarter 2008 Results HOPKINTON, Mass., May 8 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc.today reported its first quarter financial results for 2008.
First quarter revenues were $29.3 million, an increase of 3% over revenues of $28.4 million in the...
Alphatec licenses pedicle screw technology from DePuy and Biedermann Alphatec Holdings has reached a successful settlement and release agreement to license pedicle screw technology from DePuy Spine and Biedermann Motech.Pursuant to the settlement and release agreement among Alphatec and DePuy &...
Biogen Idec Commences Mailing of Proxy Materials to Shareholders CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (Nasdaq: BIIB - News) today commenced the mailing of proxy materials encouraging shareholders to vote at the companys June 19, 2008 Annual Meeting for four highly regarded and accomplished...
Par Pharmaceutical Reports First Quarter 2008 Results Reports First Quarter Adjusted EPS of $0.17 per Diluted Share Provides Full-year 2008 EPS Guidance and Projects its Pipeline Opportunities WOODCLIFF LAKE, N.J., May 8 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc.(NYSE: PRX ...
Mylan In Settlement Talks With Abbott On Generic Depakote _ Mylan In Settlement Talks With Abbott On Generic Depakote.
U.S. Air Force Pays Record Amount for Baby Injured in Government Hospital WASHINGTON, May 9 /PRNewswire/ -- The U.S.Air Force has paid a family $5 million for severe brain damage suffered by a baby during childbirth at a military hospital.
The amount is a record sum for government settlement payments to...
Glossary of veterinary malpractice legal terms Brief: n.a written legal argument stating the legal authorities and arguments in support of a petition or motion.
Cause of action: n.
the basis of a lawsuit founded on legal grounds as required by common law or statutes.
In many...
Par Pharmaceutical Reports First Quarter 2008 Results WOODCLIFF LAKE, N.J., May 8 /PRNewswire-FirstCall/ -- Par Pharmaceutical (News) Companies, Inc.today reported results for the first quarter ended March 29, 2008.
Par reported total revenues of $154.9 million and net income of $2.6...
/C O R R E C T I O N -- Insmed Inc./ The news release, Insmed Announces First Quarter 2008 Financial Results, issued earlier today by Insmed Inc., was incorrectly transmitted by PR Newswire.Complete, corrected release follows: Insmed Announces First Quarter 2008 Financial...
/C O R R E C T I O N -- Insmed Inc./ The news release, Insmed (Nasdaq: INSM - News) Announces First Quarter 2008 Financial Results, issued earlier today by Insmed Inc., was incorrectly transmitted by PR Newswire.Complete, corrected release follows: Insmed Announces First...
Insmed Announces First Quarter 2008 Financial Results RICHMOND, Va., May 8 /PRNewswire-FirstCall/ -- Insmed Inc.(Nasdaq: INSM - News), a developer of follow-on biologics (FOB) and biopharmaceuticals, today reported results for the first quarter ended March 31, 2008.
Recent Company...
Spectrum Sale of Profit Shares of Migraine Drug Nets $20M Par Owns 95 Percent of Sumatriptan Spectrum Pharmaceuticals Inc.garnered $20 million in nondilutive funds to advance its urology and oncology products by selling its profit shares of sumatriptan injection to partner Par Pharmaceutical Inc...
Spectrum Sale of Profit Shares of Migraine Drug Nets $20M PM Par Owns 95 Percent of Sumatriptan Spectrum Pharmaceuticals Inc.garnered $20 million in nondilutive funds to advance its urology and oncology products by selling its profit shares of sumatriptan injection to partner Par Pharmaceutical...
Par Pharmaceutical Reports First Quarter 2008 Results Reports First Quarter Adjusted EPS of $0.17 per Diluted Share Provides Full-year 2008 EPS Guidance and Projects its Pipeline Opportunities WOODCLIFF LAKE, N.J., May 8 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc.(NYSE: PRX ...
Mylan Reports Adjusted Diluted EPS of $0.09 for the Quarter Ended March 31, 2008 PITTSBURGH, May 8 /PRNewswire-FirstCall/ -- Mylan Inc.(NYSE: MYL) today announced its financial results for the three months ended March 31, 2008, the first quarter of its fiscal year ending December 31, 2008.
Financial Highlights --...
Cytogen Reports First Quarter 2008 Financial Results PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO - News) today reported its financial results for the first quarter of 2008.Cytogen reported a net loss of $5.9 million, or $0.16 per diluted share for the first quarter...
Local importer to stop bringing in imitation Viagra PHARMACEUTICAL company Pfizer has reached a settlement with a local importer for him to cease importation of an imitator product of the drug Viagra.Pfizer stated in a release on Tuesday a settlement had been reached with...
Sepracor Announces Final Settlement of XOPENEX(R) Inhalation Solution Patent Infringement Litigation with Brea MARLBOROUGH, Mass.--(HSMN NewsFeed)--Sepracor Inc.(Nasdaq: SEPR ) today announced that it has entered into a Settlement and License Agreement with Breath Limited (Breath), an Arrow Group subsidiary, to resolve the patent litigation...
DUSA Pharmaceuticals Reports First Quarter 2008 Corporate Highlights and Financial Results DUSA Pharmaceuticals, Inc.?(NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan?
photodynamic therapy (PDT) and other products targeting patients with common skin conditions, reported today its corporate...
DUSA Pharmaceuticals Reports First Quarter 2008 Corporate Highlights and Financial Results Q1 Levulan(R) Kerastick(R) unit sales up 36% year over year; Non-GAAP loss narrows to ($0.6) million in Q108; Pricing approval received for Levulan(R) Kerastick(R) in Brazil This article Email this page| | Tell us your thoughts Helpful links...
Meda AB (publ), January - March 2008 interim report Meda AB (publ), January March 2008 interim report The Groups net sales reached SEK 2,570 million (1,788), a 44% increase compared to last year.EBITDA increased by 55% to SEK 925 million (598), thus yielding a 36.0% margin (33.5).
